Our most advanced small-molecule drug candidate, TQS-168, completed Phase 1 clinical development and is ready to advance to phase 2 clinical trials. We obtained regulatory approval (CTA) to initiate a phase 2 trial in ALS and are preparing additional trials in other diseases including neurodegenerative and metabolic diseases.
In multiple in vivo pharmacology neurodegeneration models, TQS-168 has demonstrated excellent blood brain barrier penetration, the ability to reverse myeloid cell dysfunction through PGC1α activation, and the capacity to ameliorate disease through enhancing lysosomal acidification and the modulation of lysosomal biology.
TQS-168 has been shown to extend survival in several mouse models of neurodegenerative diseases, and has shown significant effect on frailty, muscle strength and body fat distribution in aging wildtype mice.
Restoring cell energy metabolism,
mitochondrial and lysosomal health
Our second candidate, TQS-621, has started IND-enabling work and is expected to enter clinical development in the near future. This promising follow-on compound is slated to be studied in a number of non-orphan neurodegenerative and systemic diseases, including Parkinson’s disease, Alzheimer’s disease and more.
Additionally, we have screened more than 200 molecules, representing potential next-generation PGC1α regulators and immunometabolic or inflammatory targets in adjacent myeloid cell pathways.